| 前收市價 | 31.61 |
| 開市 | 31.36 |
| 買盤 | 31.08 x 800 |
| 賣出價 | 31.97 x 900 |
| 今日波幅 | 31.19 - 31.99 |
| 52 週波幅 | 27.74 - 47.12 |
| 成交量 | |
| 平均成交量 | 821,203 |
| 市值 | 20.881B |
| Beta 值 (5 年，每月) | 0.70 |
| 市盈率 (最近 12 個月) | 33.65 |
| 每股盈利 (最近 12 個月) | 0.95 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 41.96 |
InvestorPlace7 Must-Buy Stocks That Are on Ridiculous Discount Now
Given that this may be the year of artificial intelligence, it’s no surprise that while certain enterprises have hogged the spotlight, astute investors also enjoy compelling opportunities regarding stocks on sale. To be sure, this approach requires going off the beaten path. If you’re willing to do so, the potential rewards could be enticing. Fundamentally, chasing after heavily hyped securities carry risks. Yes, rumblings in the AI sector have continued to bolster the usual suspects in the tech
InvestorPlace7 Underappreciated Biotech Stocks to Pick Up on the Cheap
Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. As a sector that, while not immune to broader pressures, generally manages to march to its own beat, the underlying innovation may offer an alternative upside pathway. By now, you’ve likely heard about the impressive third-quarter U.S. GDP print, which came in hotter than expected. But looking ahead, circumstances don’t seem so rosy to justify belief in a repeat performance.
Insider MonkeyGenmab A/S (NASDAQ:GMAB) Q3 2023 Earnings Call Transcript
Genmab A/S (NASDAQ:GMAB) Q3 2023 Earnings Call Transcript November 7, 2023 Genmab A/S beats earnings expectations. Reported EPS is $0.47, expectations were $0.34. Operator: Hello, and welcome to Genmab’s Third Quarter 2023 Financial Results Conference Call. As a reminder, this conference call is being recorded. During this telephone conference, you may be presented with forward-looking […]
